Aptose Biosciences - APTO Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APTO shares.
View APTO analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 1 year target prices for Aptose Biosciences' shares. Their APTO share price forecasts range from $5.00 to $6.00. On average, they anticipate the company's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 837.4% from the stock's current price.
View analysts price targets for APTO or view top-rated stocks among Wall Street analysts.

Aptose Biosciences' stock was trading at $0.58 at the start of the year. Since then, APTO shares have increased by 1.2% and is now trading at $0.5867.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our APTO earnings forecast.

Aptose Biosciences will be holding an earnings conference call on Thursday, March 23rd at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

Aptose Biosciences Inc. (NASDAQ:APTO) announced its quarterly earnings data on Thursday, November, 11th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.04. During the same quarter in the previous year, the business earned ($0.15) EPS.

8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com. William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX).

Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."

Aptose Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include DRW Securities LLC (9.63%), Nantahala Capital Management LLC (6.55%), Sigma Planning Corp (1.16%), Annandale Capital LLC (0.87%), Morgan Stanley (0.75%) and Voss Capital LLC (0.60%). Insiders that own company stock include Denis R Burger, Donald R Jr Wilson, Erich Platzer, Gregory K Chow, Jotin Marango, Rafael Bejar, Warren Whitehead and William G Rice.
View institutional ownership trends.

Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of APTO stock can currently be purchased for approximately $0.59.

Aptose Biosciences (NASDAQ:APTO) has a market capitalization of $54.19 million. The biotechnology company earns $-65,350,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

Aptose Biosciences' mailing address is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. The official website for the company is www.aptose.com. The biotechnology company can be reached via phone at 858-926-2730, via email at ir@aptose.com, or via fax at 905-234-2120.